During an intriguing discussion at the conference, Prof Eric Van Cutsem from UZ Leuven and Prof Richard Finn, a medical oncologist at the University of California, Los Angeles, explored the outcomes of the MORPHEUS-Liver study. This study was a phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients diagnosed with unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC).
Tiragolumab is a human anti-TIGIT monoclonal antibody, and its use in combination with other immunotherapies, such as PD-L1 inhibitors like atezolizumab, aims to enhance antitumor responses. The MORPHEUS-Liver study investigated the efficacy and safety of tiragolumab in combination with atezolizumab and bevacizumab in patients with advanced HCC.
The discussion by Prof Van Cutsem and Prof Finn delved into the outcomes of the study, shedding light on the potential benefits and synergistic effects of combining tiragolumab with the PD-L1 inhibitor atezolizumab and the angiogenesis inhibitor bevacizumab.
With the educational support of:
